Iperten

Manidipine Dihydrochloride, the active ingredient in Iperten, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to treat hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Iperten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. All shipments are handled under Good Distribution Practice, ensuring product integrity throughout the supply chain.

Iperten (manidipine dihydrochloride) is used in the management of hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Manidipine dihydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Hepatic dysfunction - Allergic reactions, including angioedema

When prescribing Iperten, clinicians should consider several safety measures to minimize risks.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Liver function: evaluate hepatic enzymes before initiating therapy. - Elderly patients: start at lower dose and monitor for orthostatic effects. - Concurrent antihypertensives: adjust doses to prevent additive blood pressure lowering. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Manidipine dihydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels leading to hypotension. - Other vasodilators (e.g., nitroglycerin): risk of additive blood pressure drop. - Grapefruit juice: can raise drug concentration and precipitate adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Beta‑blockers: monitor for combined cardiac effects.